← Back to Search

Other

Arm C: RPTR-147:2 for Lymphoma

Phase 1
Waitlist Available
Research Sponsored by Repertoire Immune Medicines
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Inclusion criteria: RPTR-147:1 (Arms A & B) treatment groups
Melanoma
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre-dose through approximately 1 year after rptr-147/pembrolizumab last dose
Awards & highlights

Study Summary

This trial is testing a new drug, RPTR-147, to see if it is safe and works well against cancer.

Eligible Conditions
  • Lymphoma
  • Solid Tumors

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-dose through approximately 1 year after rptr-147/pembrolizumab last dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-dose through approximately 1 year after rptr-147/pembrolizumab last dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Frequency of dose interruptions
Number of subjects with dose limiting toxicities
Secondary outcome measures
Area under the serum concentration-time curve
Best overall response
Immunogenicity of RPTR-147 as monotherapy and in combination with pembrolizumab
+2 more

Trial Design

3Treatment groups
Experimental Treatment
Group I: RPTR-147:2Experimental Treatment1 Intervention
Arm C: Escalating doses of RPTR-147:2 in patients with HPV-16 positive tumors
Group II: RPTR-147:1 and PembrolizumabExperimental Treatment1 Intervention
Arm B: Escalating doses of RPTR-147:1 in combination with Pembrolizumab in patients with solid tumors and lymphomas
Group III: RPTR-147:1Experimental Treatment1 Intervention
Arm A: Escalating doses of RPTR-147:1 as a monotherapy in solid tumors and lymphomas

Find a Location

Who is running the clinical trial?

Repertoire Immune MedicinesLead Sponsor
2 Previous Clinical Trials
29 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
3,865 Previous Clinical Trials
5,051,398 Total Patients Enrolled
91 Trials studying Lymphoma
8,742 Patients Enrolled for Lymphoma
Daniel Vlock, MDStudy DirectorRepertoire Immune Medicines
4 Previous Clinical Trials
54 Total Patients Enrolled
2 Trials studying Lymphoma
29 Patients Enrolled for Lymphoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Have there been prior studies conducted involving the RPTR-147:2 formulation?

"Arm C: RPTR-147:2 was first tested at City of Hope in 2010 and since then, 249 studies have been concluded. Over 900 trials are presently recruiting participants with a majority hosted in New york's metropolitan area."

Answered by AI

Has the FDA sanctioned RPTR-147:2 in Arm C?

"The risk-benefit analysis conducted by our team at Power awarded Arm C: RPTR-147:2 a score of 1 due to the limited clinical evidence supporting its safety and efficacy."

Answered by AI

How many participants are engaging in this experiment?

"This medical trial has wrapped up its recruitment process, last revised on August 30th 2022. If you are in search of alternative studies, there is an abundance with 2136 clinical trials for those diagnosed with lymphoma and 961 concerning RPTR-147:2 that still accept participants."

Answered by AI

Is the application process for this trial currently accessible?

"The information found on clinicaltrials.gov reveals that this particular investigation is not currently recruiting any participants; the initial post was made in October 2018 and last edited in August 2022. Nonetheless, there are over three thousand other studies actively seeking volunteers right now."

Answered by AI

What aims is this research seeking to achieve?

"At the conclusion of cycle 1, this trial will measure its primary outcome—the number of patients with dose-limiting toxicities. The secondary objectives include best overall response per modified RECIST v1.1 (for solid tumors) or Lugano classification (for lymphoma), immunogenicity of RPTR-147 as monotherapy and in combination with pembrolizumab measured by counting anti-RPTR/Pembro antibodies, and progression free survival evaluated using modified RECIST v1.1 for solid tumor detection or Lugano Classification for detecting lymphomas."

Answered by AI

How many locations are participating in this investigation?

"This trial is being conducted across 11 different medical sites, including NYU Langone Health in New york City, Sarah Cannon Research Institute in Nashville, and Carolina BioOncology Institute located near Huntersville."

Answered by AI

What therapeutic purpose is Arm C: RPTR-147:2 typically employed for?

"Arm C: RPTR-147:2 is a common course of treatment for malignant neoplasms and has also been used to treat unresectable melanoma, microsatellite instability high cancers, and progression after chemotherapy."

Answered by AI
~4 spots leftby Mar 2025